The enzyme inhibitor market is expected to witness growth owing to the growth of pharmaceutical drug industry. The key driver of this industry is the global spending on medicines in coalition with the increasing demand of specialty drugs. The North American region is accounted for more than 40% market share mainly due to the presence of leading players in US pharmaceutical industry. The Asia Pacific region is projected to see highest growth rate by 2022, particularly China is expected to witness more than 15% CAGR in the forecasted period.

Enzyme inhibitor is a molecule which particularly binds with an enzyme to slow down its activity. It is primarily used to kill a pathogen, which produces harmful diseases to maintain the metabolic imbalance. In Agricultural industry, it is mainly used as a pesticide to attract and destroy any pest. There are many applications of enzyme inhibitor such as chemotherapy, metabolic control, pesticides, and natural poisons. These inhibitors alter the functioning of enzymes and thus altering the gene expression. Few other important applications such as male erectile dysfunction, survival of bacterial pathogens, blocking specific protein in the pancreas, regulation of neurological functioning, and stopping toxins that pollutes environment are expected to drive the market in the near future.

Browse Detail Market Report @  

Few factors that are expected to thrust the market of enzyme inhibitor are research & development spending by pharmaceutical companies, increasing competition, and technological advancement. Upcoming new technologies have led to the new product development, which has assisted the market to expect high growth over the forecasted period. Sedentary lifestyle, pandemic threats, and higher risk of disease are few other driving factors that will fuel in the growth of the market by 2022. The key restrain that may slightly decrease the revenue growth of the market is due to the patent expiration. Last few years patent expiration has led the pharmaceutical industry to bear revenue losses of more than USD 20 billion each year, but from the strategic actions by pharmaceutical companies it is projected to go down to less than one third.

The market is segmented by reversible and irreversible as per the inhibitors binding with the enzymes. Reversible inhibitor binding with enzyme is created through non-covalent bonding such as ionic bonds or hydrogen bonds. Non-reversible inhibitor binding with enzyme is created through covalent bonding by reacting chemically with the enzyme.

Request Sample Copy of Market Research @  

The market segmentation by inhibitor type into proton pump inhibitors (PPI), phosphodiesterase type 5 (PDE5) inhibitors, protease inhibitors, neuraminidase inhibitors, aromatase inhibitors, reverse transcriptase inhibitor, statins, kinase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. These inhibitors have varied application in the pharmaceutical industry on the basis of reaction with the pathogens such as PPIs for reducing the long lasting production of gastric acid, PDE5 to treat the erectile dysfunction, protease for the treatment of HIV/AIDS, kinase to block the action of protein kinases, reverse transcriptase to generate complementary DNA, neuraminidase to block the influenza virus, statins for reducing the cholesterol production, and angiotensin for the treatment of hypertension.

The market can also be segmented by region into North America, Latin America, Europe, Asia Pacific, and Middle East. Globally, the North America has the highest market share due to the presence of largest players who produces the enzyme inhibitor drugs. Particularly the US has the top five largest pharmaceutical companies based on the revenue share. In totality, it has more than 150 companies, which are competing in the enzyme inhibitor market. Research & development spending in the US is highest among other countries of North American region.

The European region has the second highest market share of enzyme inhibitor drugs mainly due to the high government expenditure towards pharmaceutical industries and companies involvement in producing the drug. Particularly in the United Kingdom, there are companies such as GlaxoSmithKline and AstraZeneca, which accounts for maximum revenue market share of enzyme inhibitor drugs.

The Asia Pacific region is the fastest growing market mainly due to the increasing awareness of inhibitor drugs and increasing investment from foreign companies. Particularly the countries such as India, China, Japan, Russia, and Singapore accounts for more than half of the market share among other countries in the region. This is due to the high economic development, higher investments, increasing awareness, and high population. In the forecasted period, the Asia pacific region is expected to account for maximum share globally in at least 4-5 inhibitor drugs.

The key players that compete in the enzyme inhibitor market are Novartis, Pfizer, Roche, Sanofi, Merch & Co., Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Gilead Sciences, Takeda, Bayer, Astellas, Daiichi Sankyo, Baxter and Novo Nordisk. Out of these companies, Novartis and Pfizer accounts for highest revenue market share and highest R&D spending.

Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact Person:

Ryan Manuel


Contact Details:

Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016 India Phone: 91-20-65300184


Visit Our Blog:



Related posts:


Please enter your comment!
Please enter your name here